Combining erlotinib with a new‐generation AKT inhibitor caused synthetic lethal interaction in EGFR‐mutated NSCLC harboring high RHOB levels, suggesting a novel therapeutic strategy to overcome resistance in RHOB‐positive patients. Here, EGFR is linked to non-small cell lung carcinoma.